(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|
Turnover | 15.00%754.24M | -73.12%1.24B | -75.58%655.84M | 9.83%4.61B | 186.60%2.69B | 436.82%4.2B | --937M | 38.81%781.52M | --563.01M |
Operating income | 15.00%754.24M | -73.12%1.24B | -75.58%655.84M | 9.83%4.61B | 186.60%2.69B | 436.82%4.2B | 937M | 38.81%781.52M | 563.01M |
Cost of sales | -35.20%-686.13M | 75.09%-1.01B | 78.38%-507.51M | -8.67%-4.06B | -177.05%-2.35B | -420.88%-3.74B | ---847.12M | -39.61%-717.74M | ---514.11M |
Operating expenses | -35.20%-686.13M | 75.09%-1.01B | 78.38%-507.51M | -8.67%-4.06B | -177.05%-2.35B | -420.88%-3.74B | -847.12M | -39.61%-717.74M | -514.11M |
Gross profit | -54.09%68.1M | -58.44%226.62M | -56.18%148.33M | 19.36%545.3M | 276.61%338.5M | 616.20%456.84M | 89.88M | 30.44%63.79M | 48.9M |
Selling expenses | -10.54%-9.13M | 6.67%-17.37M | 13.36%-8.26M | -26.71%-18.61M | -47.32%-9.53M | -49.26%-14.69M | ---6.47M | 4.40%-9.84M | ---10.29M |
Administrative expenses | -57.19%-45.73M | 4.66%-83.08M | 11.52%-29.09M | -74.93%-87.14M | -64.86%-32.88M | -72.29%-49.82M | ---19.95M | -8.75%-28.91M | ---26.59M |
Impairment and provision | 217.23%4.21M | 94.64%-2.43M | -71.96%-3.59M | -2,040.50%-45.29M | -84.28%-2.09M | -86.43%-2.12M | ---1.13M | 20.91%-1.14M | ---1.44M |
-Other impairment is provision | 217.23%4.21M | 94.64%-2.43M | -71.96%-3.59M | -2,040.50%-45.29M | -84.28%-2.09M | -86.43%-2.12M | ---1.13M | 20.91%-1.14M | ---1.44M |
Operating interest expense | ---- | ---- | ---- | ---- | -17.82%-3M | -110.90%-8.03M | ---2.55M | -254.00%-3.81M | ---1.08M |
Special items of operating profit | 73.82%-249K | -28.67%4.36M | 54.76%-951K | -68.78%6.11M | -1,059.82%-2.1M | 101.10%19.58M | --219K | 376.97%9.74M | --2.04M |
Operating profit | -83.84%17.2M | -68.00%128.1M | -63.15%106.45M | -0.35%400.37M | 381.45%288.89M | 1,247.11%401.76M | 60.01M | 158.15%29.82M | 11.55M |
Financing cost | -28.97%-4.2M | -11.62%-5.39M | ---3.26M | ---4.83M | ---- | ---- | ---- | ---- | ---- |
Share of profits of associates | ---- | 71.07%-46K | 3.95%-73K | -102.67%-159K | -103.03%-76K | 2,021.00%5.96M | --2.51M | -70.91%281K | --966K |
Earning before tax | -87.39%13.01M | -68.97%122.67M | -64.30%103.12M | -3.03%395.38M | 362.02%288.82M | 1,254.34%407.72M | 62.51M | 140.47%30.11M | 12.52M |
Tax | -110.28%-199K | 66.05%-3.08M | 130.36%1.94M | 42.14%-9.08M | -42.19%-6.38M | -511.50%-15.69M | ---4.48M | -317.75%-2.57M | ---614K |
After-tax profit from continuing operations | -87.81%12.81M | -69.04%119.59M | -62.80%105.06M | -1.46%386.31M | 386.73%282.44M | 1,323.52%392.04M | 58.03M | 131.33%27.54M | 11.91M |
Earning after tax | -87.81%12.81M | -69.04%119.59M | -62.80%105.06M | -1.46%386.31M | 386.73%282.44M | 1,323.52%392.04M | 58.03M | 131.33%27.54M | 11.91M |
Minority profit | 267.38%3.41M | -86.76%710K | -83.72%929K | -32.57%5.36M | 102.16%5.71M | 293.91%7.95M | --2.82M | 352.06%2.02M | ---801K |
Profit attributable to shareholders | -90.98%9.39M | -68.79%118.88M | -62.37%104.13M | -0.82%380.94M | 401.29%276.74M | 1,404.98%384.09M | 55.21M | 100.86%25.52M | 12.71M |
Basic earnings per share | -92.68%0.03 | -69.80%0.45 | 0.41 | 1.49 | |||||
Diluted earnings per share | -92.68%0.03 | -69.80%0.45 | 0.41 | 1.49 | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data